Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. CorMedix Inc.
  6. News
  7. Summary
    CRMD   US21900C3088

CORMEDIX INC.

(CRMD)
  Report
Delayed Nasdaq  -  04:00 2022-09-26 pm EDT
2.850 USD   -1.04%
09/07CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
AQ
08/12Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating
MT
08/11Transcript : CorMedix Inc., Q2 2022 Earnings Call, Aug 11, 2022
CI
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Needham Adjusts CorMedix's Price Target to $12 from $20, Keeps Buy Rating

08/09/2022 | 11:01am EDT


© MT Newswires 2022
All news about CORMEDIX INC.
09/07CorMedix Inc. to Present at the H.C. Wainwright Annual Global Investment Conference
AQ
08/12Truist Securities Lowers CorMedix's Price Target to $16 From $27, Maintains Buy Rating
MT
08/11Transcript : CorMedix Inc., Q2 2022 Earnings Call, Aug 11, 2022
CI
08/11CORMEDIX INC. Management's Discussion and Analysis of Financial Condition and Results ..
AQ
08/11Cormedix : Reports SECOND Quarter AND SIX MONTH 2022 Financial Results and Provides Busine..
PU
08/11Cormedix : Q2 Earnings Snapshot
AQ
08/11Earnings Flash (CRMD) CORMEDIX Posts Q2 Revenue $21,253
MT
08/11CorMedix Inc. Reports Second Quarter and Six Month 2022 Financial Results and Provides ..
AQ
08/11CorMedix Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June..
CI
08/09Top Midday Decliners
MT
More news
Analyst Recommendations on CORMEDIX INC.
More recommendations
Financials (USD)
Sales 2022 0,01 M - -
Net income 2022 -33,9 M - -
Net cash 2022 50,3 M - -
P/E ratio 2022 -3,34x
Yield 2022 -
Capitalization 117 M 117 M -
EV / Sales 2022 6 940x
EV / Sales 2023 57,8x
Nbr of Employees 30
Free-Float 98,8%
Chart CORMEDIX INC.
Duration : Period :
CorMedix Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CORMEDIX INC.
Short TermMid-TermLong Term
TrendsBearishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 2,85 $
Average target price 14,00 $
Spread / Average Target 391%
EPS Revisions
Managers and Directors
Joseph Todisco Chief Executive Officer & Director
Mathew T. David Chief Financial Officer & Executive Vice President
Myron Lawrence Kaplan Chairman
Antony E. Pfaffle Secretary & Chief Scientific Officer
Elizabeth Masson-Hurlburt Executive VP-Clinical & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
CORMEDIX INC.-37.36%119
MERCK KGAA-30.15%67 214
KYOWA KIRIN CO. LTD.0.48%11 822
ZHEJIANG JIUZHOU PHARMACEUTICAL CO., LTD-35.71%4 161
SK BIOPHARMACEUTICALS CO., LTD.-39.61%3 297
YUHAN CORPORATION-14.17%2 633